The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://bookmarksusa.com/story21712932/tirzepatide-and-nmn-a-integrated-approach-to-general-health